RAF/MEK dependence of KRAS-mutant pancreatic ductal adenocarcinomas

Cancer Discov. 2012 Aug;2(8):666-9. doi: 10.1158/2159-8290.CD-12-0308.

Abstract

Studies using genetically engineered mouse models indicate that RAF activation is sufficient to induce pancreatic intraepithelial neoplasms, suggesting that mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase (MEK) inhibitor-based combination approaches may have clinical use in patients with pancreatic ductal adenocarcinomas.

Publication types

  • Comment

MeSH terms

  • Animals
  • Carcinoma, Pancreatic Ductal / enzymology*
  • Cell Transformation, Neoplastic / metabolism*
  • Extracellular Signal-Regulated MAP Kinases / metabolism*
  • Humans
  • MAP Kinase Signaling System*
  • Mitogen-Activated Protein Kinase Kinases / metabolism*
  • Pancreatic Neoplasms / enzymology*
  • Proto-Oncogene Proteins B-raf / metabolism*

Substances

  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf
  • Extracellular Signal-Regulated MAP Kinases
  • Mitogen-Activated Protein Kinase Kinases